2024-12-14 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis Report

**1. Performance Comparison & Overview:**

Johnson & Johnson is a multinational corporation that manufactures medical devices, pharmaceuticals, and consumer packaged goods.  

The cumulative return for JNJ is 25.34%, significantly lagging behind the S&P 500's (VOO) cumulative return of 120.91%.  The difference is -95.6%, placing it at the 1st percentile (relative divergence of 1.0) of its historical performance range against the S&P 500.  This indicates considerable underperformance compared to the broader market.

The provided CAGR data shows inconsistent performance over the years, with some periods exceeding the market and others significantly underperforming.  The consistently low or negative Alpha suggests JNJ hasn't consistently outperformed the market after adjusting for risk (Beta).

**2. Recent Price Movement:**

* **Closing Price:** $146.62
* **5-Day Moving Average:** $147.67
* **20-Day Moving Average:** $151.62
* **60-Day Moving Average:** $156.68

The price is below all three moving averages, suggesting a potential downward trend.

**3. Technical Indicators & Expected Return:**

* **RSI:** 18.54 (deeply oversold territory)
* **PPO:** -0.32 (negative, indicating bearish momentum)
* **Recent Relative Divergence:** 1.0 (+) indicating a short-term upward movement. However, this is overshadowed by the long-term negative trends.
* **Expected Return:** 0.0% (This figure needs further clarification and context.  A 0% expected return is unlikely and suggests that this figure should not be relied upon. Long-term investment should be predicated on a more thorough analysis including risk factors)


Given the low RSI and negative PPO, the current price of $146.59 isn't showing signs of a significant rebound; rather, it points towards continued downward pressure unless there is a significant catalyst.  More information is required to account for the 0% expected return.

**4. Recent Earnings Analysis:**

The provided earnings data shows a mixed picture:

* **EPS:** Fluctuates significantly between quarters, with a substantial drop in Q3 2023 ($10.32) possibly due to accounting changes. The consistent reduction in reported EPS in subsequent quarters warrants deeper investigation, especially a detailed explanation to understand why Q3 2023 reported EPS is an order of magnitude larger.
* **Revenue:** Revenue remains relatively stable, with minor fluctuations around $22 billion.  There's no clear upward or downward trend observable.

Without context, such as industry benchmarks and expectations, it's impossible to definitively classify these results as "beats" or "misses."


**5. Financial Information Analysis:**

* **Revenue & Profitability:** Revenue is relatively stable, and Profit Margins remain consistent at around 69%, implying consistent profitability despite minor revenue fluctuations.
* **Capital & Profitability:** Equity fluctuates, and ROE shows inconsistency, with a dramatic spike in Q3 2023 (36.54%), followed by a significant decline. This requires further investigation to ascertain the cause.  The unusual Q3 2023 ROE needs to be explained, and this may be affected by the unusually high Q3 EPS which requires further investigation.

In summary, the financial statements illustrate a need for more contextual information to provide accurate and complete analysis.

**6. News and Recent Issues:**

* **Earnings News:** No recent earnings news is available in the given context.  An earnings press release or more complete financial statements would provide more comprehensive information to complete an analysis.
* **Market Outlook & Analyst Opinions:**  This information is missing from the provided data.  Further research into analyst reports and market sentiment is necessary for a more complete picture.


**7. Overall Analysis:**

JNJ has significantly underperformed the S&P 500 over the period analyzed. While the recent price suggests an oversold condition based on the low RSI,  the negative PPO and recent price action below moving averages indicates a persistent bearish trend.  The inconsistent EPS and ROE figures raise concerns, and require detailed review. Additional data, such as analyst reports and market outlooks, is crucial for a more informed investment decision. The 0% expected return is not considered to be a reliable forecast, and further clarification is needed.


**8. Recommendations:**

Given the presented data, a more in-depth analysis is needed before making any investment recommendations.  Further investigation should focus on:

* Understanding the reasons for the extreme Q3 2023 EPS and ROE values.
* Reviewing analyst reports and market sentiment.
* Investigating the source of the 0% expected return figure, and obtaining a more realistic forecast.
* Comparing JNJ's performance to its peers in the pharmaceutical and consumer goods sectors.

Only after gaining a comprehensive understanding of these factors can a well-informed investment decision be made.  The current data suggests that JNJ's underperformance relative to the S&P 500 warrants caution.
